ACAD
31.7
0.00
0.00%
AEMD
0.25
-0.02
-6.81%
APRI
1.22
0.00
0.00%
ARNA
4.77
0.00
0.00%
ATEC
1.32
0.00
0.00%
CFN
59.74
0.00
0.00%
CNAT
6.09
0.00
0.00%
CRXM
0.2
0.00
-0.01%
CYTX
0.5
0.00
0.00%
DXCM
62.32
0.00
0.00%
GNMK
13.51
0.00
0.00%
HALO
14.48
0.00
0.00%
ILMN
203.25
0.00
0.00%
INNV
0.2
-0.03
-11.16%
INO
8.94
0.00
0.00%
ISCO
0.06
0.00
0.00%
ISIS
72.4
0.00
0.00%
LGND
58.56
0.00
0.00%
LPTN
2.94
0.00
0.00%
MBVX
1.11
-0.06
-5.13%
MEIP
3.69
0.00
0.00%
MNOV
3.46
0.00
0.00%
MRTX
20.98
0.00
0.00%
MSTX
0.46
0.00
0.00%
NBIX
33.54
0.00
0.00%
NUVA
46.93
0.00
0.00%
ONCS
0.39
0.00
-0.88%
ONVO
6.59
0.00
0.00%
OREX
5.67
0.00
0.00%
OTIC
34.42
0.00
0.00%
QDEL
24.96
0.00
0.00%
RCPT
116.69
0.00
0.00%
RGLS
18.9
0.00
0.00%
RMD
65.2
0.00
0.00%
SCIE
0.01
0.00
0.00%
SPHS
0.49
0.00
0.00%
SRNE
10.62
0.00
0.00%
TROV
5.95
0.00
0.00%
VICL
1.03
0.00
0.00%
VOLC
17.97
0.00
0.00%
ZGNX
1.39
0.00
0.00%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.